JP2025515346A5 - - Google Patents
Info
- Publication number
- JP2025515346A5 JP2025515346A5 JP2024563505A JP2024563505A JP2025515346A5 JP 2025515346 A5 JP2025515346 A5 JP 2025515346A5 JP 2024563505 A JP2024563505 A JP 2024563505A JP 2024563505 A JP2024563505 A JP 2024563505A JP 2025515346 A5 JP2025515346 A5 JP 2025515346A5
- Authority
- JP
- Japan
- Prior art keywords
- bont
- muscle
- unit dose
- dose
- unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2206361.4A GB202206361D0 (en) | 2022-04-29 | 2022-04-29 | Treatment of a facial dystonia |
| GB2206361.4 | 2022-04-29 | ||
| PCT/GB2023/050746 WO2023209327A1 (en) | 2022-04-29 | 2023-03-23 | Bont/a for use in treating a facial dystonia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515346A JP2025515346A (ja) | 2025-05-14 |
| JP2025515346A5 true JP2025515346A5 (enExample) | 2026-03-30 |
Family
ID=81943823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024563505A Pending JP2025515346A (ja) | 2022-04-29 | 2023-03-23 | 顔面ジストニアを治療する用途のＢｏＮＴ／Ａ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250213662A1 (enExample) |
| EP (1) | EP4514824A1 (enExample) |
| JP (1) | JP2025515346A (enExample) |
| KR (1) | KR20250004870A (enExample) |
| CN (1) | CN119095868A (enExample) |
| AU (1) | AU2023262229A1 (enExample) |
| CA (1) | CA3245925A1 (enExample) |
| GB (1) | GB202206361D0 (enExample) |
| WO (1) | WO2023209327A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025093844A1 (en) * | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| ATE518882T1 (de) | 2005-09-19 | 2011-08-15 | Allergan Inc | Mit clostridientoxin aktivierbare clostridientoxine |
| AU2010236613B2 (en) | 2009-04-14 | 2016-07-07 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
| US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
| ES2708661T3 (es) | 2011-05-19 | 2019-04-10 | Ipsen Bioinnovation Ltd | Métodos para la fabricación de polipéptidos proteolíticamente procesados |
| UA116985C2 (uk) | 2012-05-30 | 2018-06-11 | Президент Енд Феллоуз Оф Гарвард Колледж | Рекомбінантний ботулінічний нейротоксин |
| WO2014079495A1 (en) | 2012-11-21 | 2014-05-30 | Syntaxin Limited | Methods for the manufacture of proteolytically processed polypeptides |
| PT3274364T (pt) | 2015-03-26 | 2021-11-05 | Harvard College | Neurotoxina botulínica manipulada |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3481852B1 (en) | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| GB202003813D0 (en) * | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| EP4404955A1 (en) * | 2021-09-23 | 2024-07-31 | Ipsen Biopharm Limited | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject |
-
2022
- 2022-04-29 GB GBGB2206361.4A patent/GB202206361D0/en not_active Ceased
-
2023
- 2023-03-23 KR KR1020247039346A patent/KR20250004870A/ko active Pending
- 2023-03-23 US US18/851,469 patent/US20250213662A1/en active Pending
- 2023-03-23 JP JP2024563505A patent/JP2025515346A/ja active Pending
- 2023-03-23 WO PCT/GB2023/050746 patent/WO2023209327A1/en not_active Ceased
- 2023-03-23 CA CA3245925A patent/CA3245925A1/en active Pending
- 2023-03-23 AU AU2023262229A patent/AU2023262229A1/en active Pending
- 2023-03-23 EP EP23715585.8A patent/EP4514824A1/en active Pending
- 2023-03-23 CN CN202380036925.9A patent/CN119095868A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2335281T3 (es) | Tratamiento de trastornos y afecciones neuromusculares con un serotipo botulinico diferente. | |
| US5298019A (en) | Controlled administration of chemodenervating pharmaceuticals | |
| JP2024534541A5 (enExample) | ||
| EP1591129B1 (en) | Use of the neurotoxic component of botulinum toxin for treating pain associated with cervical dystonia | |
| EP3423084B1 (en) | Composition comprising botulinum toxin | |
| Dressler | Botulinum toxin for treatment of dystonia | |
| JP2025515346A5 (enExample) | ||
| Bell et al. | Pharmacotherapy with botulinum toxin: harnessing nature's most potent neurotoxin | |
| Thakker et al. | Pharmacology and clinical applications of botulinum toxins A and B | |
| EP2085093A1 (en) | Preparation containing highly purified botulinum toxin type a derived from infant botulism pathogen | |
| US20230414729A1 (en) | Treatment of stress disorders using acetylcholine release inhibiting neurotoxic proteins to reduce stress levels | |
| Spósito | New indications for botulinum toxin type A in treating facial wrinkles of the mouth and neck | |
| RU2123837C1 (ru) | Способ устранения морщин | |
| TW202435908A (zh) | 組成物及應用其之注射裝置 | |
| Lipham et al. | Getting Started: Commercially Available Products, Basic Equipment and Supplies, Reconstitution and Dilution Recommendations, and Clinical Implementation | |
| RU2024129712A (ru) | Bont/a для применения в лечении дистонии лица | |
| RU2024110933A (ru) | Модифицированный bont/a для применения при лечении нарушения, поражающего мышцу века у субъекта | |
| Ginsberg et al. | Botulinum Toxin Treatment of Neurogenic Detrusor Overactivity and Overactive Bladder | |
| RU2835617C1 (ru) | Лечение морщин на лице высокой дозой и малым объемом ботулинического токсина | |
| US20250295740A1 (en) | Neurotoxin Compositions with Increased Efficacy and Effect Duration | |
| Rauh et al. | Botolinum neurotoxin: its history and use in dermatology. | |
| Monheit et al. | Basic science: abobotulinum toxin A | |
| KR20250113431A (ko) | 목을 재생하기 위한 고 농도 보툴리눔 독소 치료 | |
| CN118251232A (zh) | 肉毒神经毒素组合物 | |
| RU2025130480A (ru) | Лечение головной боли ботулиническим нейротоксином А |